Paul M. Barr, MD, discusses the clinical implications of the long-term results of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.
Paul M. Barr, MD, an associate professor of medicine and director of the Clinical Trials Office at the Wilmot Cancer Institute of the University of Rochester Medical Center, discusses the clinical implications of the long-term results of the phase 3 RESONATE-2 trial (NCT01722487) in chronic lymphocytic leukemia (CLL).
During the 2021 ASCO Annual Meeting, updated findings from the RESONATE-2 trial were presented. The results demonstrated sustained progression-free survival (PFS) and overall survival benefit with frontline ibrutinib (Imbruvica) at a follow-up of up to 7 years in patients with CLL.
These findings represent the longest follow-up to date from a phase 3 study of first-line BTK inhibitor therapy in CLL , says Barr. Notably, although patients are not yet being cured of their CLL, the long-term disease control that ibrutinib can provide without cumulative or late-onset toxicities is a significant advance in the treatment of patients with this disease, concludes Barr.